MedTrace Logo

A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients

NCT00088140 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2012-08-13

No results posted yet for this study

Summary

The purpose of this study is to determine if IDN-6556, when given orally, is safe and effective in patients with chronic hepatitis C virus infection.

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

IDN-6556

DRUG

Placebo

Sponsors & Collaborators

  • Idun Pharmaceuticals

    collaborator INDUSTRY

  • Conatus Pharmaceuticals Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2005-10-31
Completion
2005-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00088140 on ClinicalTrials.gov